Evidence map›Paper›PMID 30426231›Full record

ArticleMedical oncology (Northwood, London, England)2018

Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.

Luma Dayane de Carvalho Filiú-Braga, Teresa Raquel Tavares Serejo, Antonio Roberto Lucena-Araujo, Francisco Assis Rocha Neves, Juliana Lott de Carvalho, Eduardo Magalhaes Rego, Felipe Saldanha-Araujo

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Luma Dayane de Carvalho Filiú-BragaLaboratório de Farmacologia Molecular, Universidade de Brasília, Brasília, DF, Brazil.
Teresa Raquel Tavares SerejoLaboratório de Farmacologia Molecular, Universidade de Brasília, Brasília, DF, Brazil.
Antonio Roberto Lucena-AraujoLaboratório de Hematologia, Universidade Federal de Pernambuco, Recife, PE, Brazil.
Francisco Assis Rocha NevesLaboratório de Farmacologia Molecular, Universidade de Brasília, Brasília, DF, Brazil.
Juliana Lott de CarvalhoLaboratório de Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil.
Eduardo Magalhaes RegoLaboratório de Hematologia, Universidade de São Paulo, Ribeirão Prêto, SP, Brazil.
Felipe Saldanha-AraujoLaboratório de Farmacologia Molecular, Universidade de Brasília, Brasília, DF, Brazil. felipearaujo@unb.br.ORCID http://orcid.org/0000-0002-4200-0821
Universidade de Brasília · BRUniversidade Católica de Brasília · BRUniversidade de Ribeirão Preto · BRUniversidade Federal de Pernambuco · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The acquisition of complex karyotypes is related to the progression of chronic lymphocytic leukemia (CLL) and patients with this condition have a poor prognosis. Despite recent advances in the classification of prognosis in CLL patients, understanding of the molecular mechanisms that lead to genomic instability and progression of this disease remains inadequate. Interestingly, dysregulated expression of KDM4 members is involved in the progression of several cancer types and plays a role in the DNA damage response; however, the gene expression profile and the importance of KDM4 members in CLL are still unknown. Here, we assessed the gene expression profile of KDM4A, KDM4B, and KDM4C in 59 CLL samples and investigated whether these histone demethylases have any influence on the prognostic markers of this leukemia. KDM4A gene expression was higher in CLL patients as compared with control samples. In contrast, CLL samples showed decreased levels of the KDM4B transcript in relation to control cases, and no difference was detected in KDM4C expression. Furthermore, patients with positive expression of ZAP-70 had lower expression of KDM4B and KDM4C as compared with ZAP-70-negative patients. More importantly, patients with low expression of these histone demethylases had higher leukemic cell numbers and displayed adverse cytogenetic findings and the acquisition of a complex karyotype. The present data clearly show that the expression of KDM4 members is dysregulated in CLL and impact the prognosis of this leukemia. These findings are useful for a better understanding of the impact of epigenetics on CLL progression.

Indexed as

AdultAgedAged, 80 and overFemaleHumansJumonji Domain-Containing Histone DemethylasesLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedTranscriptomeZAP-70 Protein-Tyrosine KinaseJumonji Domain-Containing Histone DemethylasesKDM4A protein, humanKDM4B protein, humanKDM4C protein, humanZAP70 protein, humanZAP-70 Protein-Tyrosine KinaseChronic lymphocytic leukemiaKaryotypeKDM4Prognostic factorsZAP-70

Identifiers

PMID30426231
OpenAlexW2901656766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.